Amgen, others fall short in replicating study results

Biotech companies often fail to replicate the promising results from academic studies, presenting a significant hurdle to translating lab discoveries into medicines. The Wall Street Journal covered the problem in a story Friday, citing biotech giant Amgen's ($AMGN) inability to replicate Boston scientists' study involving a potential protein target for cancer drugs. "I was disappointed but not surprised," Amgen's Glenn Begley told the WSJ. Article (sub. req.)

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.